
Hims & Hers Expands Europe with ZAVA Acquisition and New Obesity Drug Offerings
Hims & Hers shares rose about 6% after announcing the acquisition of European healthcare provider Zava, expanding its presence into the UK, Germany, France, and Ireland, with the deal expected to close in the second half of the year and be profitable by 2026. The company is focusing on international growth and new health treatments, including hormone therapies, supported by recent capital raises and strategic partnerships.

